Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial

Lotan, Yair; Inman, Brant A.; Davis, Leah; Kassouf, Wassim; Messing, Edward M.; Daneshmand, Siamak; Canter, Daniel; Marble, H. Tony; Joseph, Ajith M.; Jewell, Susan; Boorjian, Stephen A.

doi:10.1097/ju.0000000000000355

Cited by 20 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the information would not be available to guide the clinical management of the individual patient regarding the decision to embark on an intravesical BCG treatment regimen. In a small prospective study, Lotan and others noted a positive FISH test prior to BCG to be associated with recurrence and progression, hazard ratio HR 2.59 (95% CI 1.42–4.73) [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study

Murakami

Kamat

Dai

et al. 2022

CBM

View full text Add to dashboard Cite

BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80–0.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study

Murakami

Kamat

Dai

et al. 2022

CBM

View full text Add to dashboard Cite

show abstract

“…In this prospective multicenter study the accuracy of the UroVysionÒ test was analyzed by Lotan et al (page 920) in patients with high grade nonmuscle invasive bladder cancer scheduled to receive intravesical bacillus Calmette-Gu erin. 9 UroVysion was associated with a hazard ratio for recurrence or progression of 2.59 at baseline, 1.94 at 6 weeks and 3.22 at 3 months. A patient with a positive result at all 3 time points had a recurrence or progression event 55% of the time while negative results at each time point had no event 76% of the time.…”

Section: Test To Predict Bladder Cancer Recurrence And/or Progressionmentioning

confidence: 95%

This Month in Adult Urology

Smith¹

2019

Journal of Urology

View full text Add to dashboard Cite

“…Freund et al (2019) reported a significant correlation of recurrence in patients with intermediate-and high-risk UC originated from the bladder after intravesical BCG therapy and a positive UroVysion test 3 months following TURBT (35). A recent prospective, multicenter diagnostic trial followed previous results showing that a UroVysion positive result indicated a risk of recurrence (48). Though many studies suggest the effectiveness of a UroVysion test as a marker of BCa recurrence, some studies suggest the contrary.…”

Section: Bca Surveillance After Intravesical Therapymentioning

confidence: 98%

UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives

Nagai¹,

Naiki²,

Etani³

et al. 2021

Transl Androl Urol

View full text Add to dashboard Cite

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial

Cited by 20 publications

References 0 publications

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study

This Month in Adult Urology

UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives

Contact Info

Product

Resources

About